Paper29799080
The challenge of drug resistance in cancer treatment: a current overview.
Nikolaou M and 3 others. Clin Exp Metastasis, 2018. Cited by 415 papers, by iCite.
Cite this record
ConductScience Library. The challenge of drug resistance in cancer treatment: a current overview. Papers, record 29799080. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29799080
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics3
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Drug Resistance, Neoplasm | Major topic |
| Neoplasms | Major topic |
| Humans |
Source PubMed
References125
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 16518375 | Targeting multidrug resistance in cancer. | Nat Rev Drug Discov | 2006 | https://conductscience.org/library/papers/16518375 | PubMed |
| 2 | 7642470 | Clinical resistance to antimetabolites. | Hematol Oncol Clin North Am | 1995 | https://conductscience.org/library/papers/7642470 | PubMed |
| 3 | 421240 | Tumour cell proliferation in relation to the vasculature. | Cell Tissue Kinet | 1979 | https://conductscience.org/library/papers/421240 | PubMed |
| 4 | 16636113 | Evolution of resistance during clonal expansion. | Genetics | 2006 | https://conductscience.org/library/papers/16636113 | PubMed |
| 5 | 16980606 | ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. | Ann Oncol | 2006 | https://conductscience.org/library/papers/16980606 | PubMed |
| 6 | 12570657 | Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. | Curr Cancer Drug Targets | 2003 | https://conductscience.org/library/papers/12570657 | PubMed |
| 7 | 7563202 | Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833. | J Natl Cancer Inst | 1995 | https://conductscience.org/library/papers/7563202 | PubMed |
| 8 | 356975 | Cell kinetics and chemotherapy: a critical review. | Cancer Treat Rep | 1978 | https://conductscience.org/library/papers/356975 | PubMed |
| 9 | 11498354 | Tumor cell resistance to DNA topoisomerase II inhibitors: new developments. | Drug Resist Updat | 1999 | https://conductscience.org/library/papers/11498354 | PubMed |
| 10 | 11261316 | An explicit representation of the Luria-Delbrück distribution. | J Math Biol | 2001 | https://conductscience.org/library/papers/11261316 | PubMed |
| 11 | 22356866 | Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance. | Drug Resist Updat | 2012 | https://conductscience.org/library/papers/22356866 | PubMed |
| 12 | 22397650 | Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. | N Engl J Med | 2012 | https://conductscience.org/library/papers/22397650 | PubMed |
| 13 | 17323126 | Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy. | Cancer Metastasis Rev | 2007 | https://conductscience.org/library/papers/17323126 | PubMed |
| 14 | 27924014 | The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. | Nucleic Acids Res | 2017 | https://conductscience.org/library/papers/27924014 | PubMed |
| 15 | 25928015 | FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance. | Mol Cancer | 2015 | https://conductscience.org/library/papers/25928015 | PubMed |
| 16 | 23002210 | Intratumor heterogeneity: evolution through space and time. | Cancer Res | 2012 | https://conductscience.org/library/papers/23002210 | PubMed |
| 17 | 6197002 | Continuous infusion or bolus injection in cancer chemotherapy. | Ann Intern Med | 1983 | https://conductscience.org/library/papers/6197002 | PubMed |
| 18 | 17234123 | Defeating drug resistance in cancer. | Discov Med | 2006 | https://conductscience.org/library/papers/17234123 | PubMed |
| 19 | 16382445 | Regional activation of chromosomal arm 7q with and without gene amplification in taxane-selected human ovarian cancer cell lines. | Genes Chromosomes Cancer | 2006 | https://conductscience.org/library/papers/16382445 | PubMed |
| 20 | 3130070 | Hypoxic cells as specific drug targets for chemotherapy. | Anticancer Drug Des | 1987 | https://conductscience.org/library/papers/3130070 | PubMed |
Cited by264
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 415 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42897892 | Profiling Extrachromosomal Circular DNA (ecDNA) in Cancer via Next-Generation Sequencing: A New Frontier in Tumor Evolution and Therapy Resistance. | Anticancer Agents Med Chem | 2026 | https://conductscience.org/library/papers/42897892 | PubMed |
| 42812781 | Unravelling therapeutic resistance: role of cancer stem cell and microRNA in metastatic prostate cancer. | Front Mol Biosci | 2026 | https://conductscience.org/library/papers/42812781 | PubMed |
| 42811363 | Uncovering pan-cancer signatures of chemoresistance. | Genome Med | 2026 | https://conductscience.org/library/papers/42811363 | PubMed |
| 42803866 | Design, green synthesis, and anticancer evaluation of novel sulfaguanidine-based heterocycles as multi-target inhibitors of the VEGFR-2/PI3K/AKT/mTOR pathway. | Mol Cell Biochem | 2026 | https://conductscience.org/library/papers/42803866 | PubMed |
| 42757169 | Targeting cancer hallmarks with microbiome-derived bacteriocins and postbiotics: molecular mechanisms and translational opportunities in oncology. | Front Oncol | 2026 | https://conductscience.org/library/papers/42757169 | PubMed |
| 42684565 | Integrated roles of miR-125b, miR-375, and miR-451 in breast cancer chemoresistance: mechanistic insights and translational implications. | Mol Biol Rep | 2026 | https://conductscience.org/library/papers/42684565 | PubMed |
| 42669594 | Natural Product Toosendanin Suppresses the Malignant Development of Skin Melanoma by Targeting BNC2 for Degradation. | Adv Sci (Weinh) | 2026 | https://conductscience.org/library/papers/42669594 | PubMed |
| 42321357 | Allicin-loaded soluplus polymeric micelles differentially modulate doxorubicin response in adenocarcinoma and myocardial cell models. | Sci Rep | 2026 | https://conductscience.org/library/papers/42321357 | PubMed |
| 42312160 | Unveiling the Role of Glutathione S‑transferase Protein in Breast Cancer Drug Resistance: Insights into the Signaling Pathways and Therapeutic Implications. | ACS Pharmacol Transl Sci | 2026 | https://conductscience.org/library/papers/42312160 | PubMed |
| 42277467 | Innovative strategies to overcome cancer drug resistance: from nanodelivery systems to targeted therapeutics. | Discov Oncol | 2026 | https://conductscience.org/library/papers/42277467 | PubMed |
| 42215431 | Ferroptosis vulnerability of enzalutamide resistant prostate cancer conferred by ACSL4 overexpression and GPX4 antagonism. | Cell Death Dis | 2026 | https://conductscience.org/library/papers/42215431 | PubMed |
| 42212337 | Neutrophil Extracellular Traps in Pancreatic Ductal Adenocarcinoma: A Vicious Cycle in the Tumor Microenvironment and Targeted Interventions. | Int J Biol Sci | 2026 | https://conductscience.org/library/papers/42212337 | PubMed |
| 42198418 | A Fivefold Maximum Drug-Likeness Strategy for Prioritizing Antibacterial Candidates Against Escherichia coli. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/42198418 | PubMed |
| 42196226 | Two Worlds, One Battle: How Bacteria and Malignancies Converge on Drug Resistance. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42196226 | PubMed |
| 42036657 | Integrated transcriptomic and proteomic analysis of cancer-suppressive Mesocestoides corti larvae. | Parasit Vectors | 2026 | https://conductscience.org/library/papers/42036657 | PubMed |
| 41831174 | Genomic profiling enables personalized strategies to overcome drug resistance in multiple myeloma. | Discov Oncol | 2026 | https://conductscience.org/library/papers/41831174 | PubMed |
| 41822854 | Therapeutic Potential of Silver Nanoparticles in Hepatocellular Carcinoma: From Pathogenesis to Clinical Perspectives. | Int J Nanomedicine | 2026 | https://conductscience.org/library/papers/41822854 | PubMed |
| 41793674 | Metabolite Profiling and Network Pharmacology of Persimmon Vinegar (Diospyros kaki) Compounds, with in silico Validation for Non-Small Cell Lung Cancer Therapy. | Asian Pac J Cancer Prev | 2026 | https://conductscience.org/library/papers/41793674 | PubMed |
| 41754887 | Navigating the Challenges of Metallopharmaceutical Agents: Strategies and Predictive Modeling for Skin Cancer Therapy. | Pharmaceutics | 2026 | https://conductscience.org/library/papers/41754887 | PubMed |
| 41751863 | Posidonia oceanica (L.) Delile in Focus: In Vitro and In Vivo Evidence for Biomedical Potential. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/41751863 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/29799080
GET https://conductscience.org/api/papers/v1/29799080/references?page=2